Role of Pharmacogenomics in Drug Development – An Industry ...
Role of Pharmacogenomics in Drug Development – An Industry ... Role of Pharmacogenomics in Drug Development – An Industry ...
Abacavir HSR and HLA B*5701Performance characteristics among ethnic groupsStudyGroupCasennp valueSensitivitySpecificityPPVNPVOR(95%CI)CNA30027Whites56744x10 -1457%99%69%98%97(12-751)CNA30032Whites1821678x10 -2348%96%37%97%21(10-48)CNA30032Hispanics51532x10 -422%100%100%95%30(2-531)CNA30032Blacks37410.278%98%12%96%4(0-36)Mallalet al18167
Abacavir HSR Prospective PGx study• A prospective study evaluate the utility ofHLA-B*5701 screening on Abacavir HSR rate• 6 weeks treatment with Abacavir containingantiviral regimens (2 x 900 patients)• Comparison of HSR rates between patients– Receiving current standard of care (all comers)versus– Prospective HLA-B*5701 screening and inclusion ofmarker negative patients (marker positive patientsexcluded)
- Page 1 and 2: Role of Pharmacogenomics inDrug Dev
- Page 3 and 4: Variation in medicine response to c
- Page 5 and 6: GSK Pharmacogenetic StrategyOngoing
- Page 7 and 8: Efficacy PGx: Opportunities• Asso
- Page 9 and 10: APOE4 - a susceptibility gene varia
- Page 11 and 12: ADAS-Cog Score in APOE ε4-Negative
- Page 13 and 14: Rosiglitazone in ADPhase III progre
- Page 15: Abacavir and Hypersensitivity (HSR)
- Page 19 and 20: PPARγ agonist FarglitazarOedema AE
- Page 21 and 22: Farglitazar oedema AE PGxSCNN1B Gen
- Page 23 and 24: Ethical considerations• PGx is no
Abacavir HSR and HLA B*5701Performance characteristics among ethnic groupsStudyGroupCasennp valueSensitivitySpecificityPPVNPVOR(95%CI)CNA30027Whites56744x10 -1457%99%69%98%97(12-751)CNA30032Whites1821678x10 -2348%96%37%97%21(10-48)CNA30032Hispanics51532x10 -422%100%100%95%30(2-531)CNA30032Blacks37410.278%98%12%96%4(0-36)Mallalet al18167
Change language